Phase IV REPLACE study met its primary endpoint in pulmonary arterial hypertension patients who transitioned to riociguat after insufficient response to PDE5 inhibitors

Study (n=226) reports 41% of patients transitioning to riociguat achieved the composite primary endpoint of clinical improvement without clinical worsening vs 20% in the sildenafil or tadalafil PDE5i group (odds ratio [OR] =2.78, 95% CI 1.53-5.06; p=0.0007).


Biospace Inc.